Results 51 to 60 of about 208,828 (307)

Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing

PLoS Pathogens, 2014
Persistent latent reservoir of replication-competent proviruses in memory CD4 T cells is a major obstacle to curing HIV infection. Pharmacological activation of HIV expression in latently infected cells is being explored as one of the strategies to ...
D. Wei, Vicki Chiang, Elizabeth Fyne, M. Balakrishnan, Tiffany L. Barnes, M. Graupe, J. Hesselgesser, A. Irrinki, J. Murry, G. Stepan, Kirsten M. Stray, A. Tsai, Helen Yu, J. Spindler, Mary F. Kearney, C. Spina, D. McMahon, J. Lalezari, D. Sloan, J. Mellors, R. Geleziunas, T. Cihlář   +21 more
semanticscholar   +1 more source

Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma. [PDF]

, 2017
SHH Medulloblastoma (SHH-MB) is a pediatric brain tumor characterized by an inappropriate activation of the developmental Hedgehog (Hh) signaling. SHH-MB patients treated with the FDA-approved vismodegib, an Hh inhibitor that targets the transmembrane ...
Bufalieri, Francesca, Canettieri, Gianluca, Capalbo, Carlo, Coni, Sonia, DE SMAELE, Enrico, Di Magno, L, DI MARCOTULLIO, Lucia, Ferretti, Elisabetta, Kusio Kobialka, M, Mai, Antonello, Mancuso, ANNA BARBARA, Manni, Simona, Niewiadomski, P, Petroni, Marialaura, Rotili, Dante, Screpanti, Isabella, Sdruscia, Giulia, Serrao, SILVIA MARIA, Spiombi, Eleonora   +18 more
core   +8 more sources

In silico profiling of histone deacetylase inhibitory activity of compounds isolated from Cajanus cajan

Beni-Suef University Journal of Basic and Applied Sciences, 2022
Background Cancer is responsible for high morbidity and mortality globally. Because the overexpression of histone deacetylases (HDACs) is one of the molecular mechanisms associated with the development and progression of some diseases such as cancer ...
Kayode Adewole, Adebayo Ishola, Ige Olaoye   +2 more
doaj   +1 more source

The Impact of Histone Modifications in Endometriosis Highlights New Therapeutic Opportunities

Cells, 2023
Endometriosis is a chronic disorder of the female reproductive system which afflicts a great number of women worldwide. Histone deacetylases (HDACs) prevent the relaxation of chromatin, thereby positively or negatively modulating gene transcription.
Iason Psilopatis, Kleio Vrettou, Florian Nima Fleckenstein, Stamatios Theocharis   +3 more
doaj   +1 more source

Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer [PDF]

, 2019
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, incurable cancer with a 20% 1 year survival rate. While standard-of-care therapy can prolong life in a small fraction of cases, PDAC is inherently resistant to current treatments, and novel ...
Adile, Ashley A., Bakhshinyan, David, Berger-Becvar, Angelika, de Araujo, Elvin D., Deininger, Michael W., Fishel, Melissa L., Gawel, Justyna M., Geletu, Mulu, Grimard, Michelle L., Gunning, Patrick T., Heaton, William L., Konieczny, Stephen F., Luchman, H. Artee, O'Hare, Thomas, Raouf, Yasir, Shah, Fenil, Shouksmith, Andrew E., Singh, Sheila K., Venugopal, Chitra, Weiss, Samuel   +19 more
core   +3 more sources

Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells

Molecular Cancer Therapeutics, 2014
The bromodomain and extra-terminal (BET) protein family members, including BRD4, bind to acetylated lysines on histones and regulate the expression of important oncogenes, for example, c-MYC and BCL2.
W. Fiskus, Sunil Sharma, J. Qi, J. Valenta, Leasha J. Schaub, B. Shah, K. Peth, B. Portier, Melissa Rodriguez, S. Devaraj, Ming Zhan, J. Sheng, S. Iyer, J. Bradner, K. Bhalla   +14 more
semanticscholar   +1 more source

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

OncoTarget, 2014
There is an unmet need to develop new, more effective and safe therapies for the aggressive forms of triple negative breast cancers (TNBCs). While up to 20% of women under 50 years of age with TNBC harbor germline mutations in BRCA1, and these tumors are
Kyungsoo Ha, W. Fiskus, D. Choi, Srividya Bhaskara, L. Cerchietti, S. Devaraj, B. Shah, Sunil Sharma, Jenny C. Chang, A. Melnick, S. Hiebert, K. Bhalla   +11 more
semanticscholar   +1 more source

Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia

Haematologica, 2008
LBH589 is a novel cinnamic hydroxamic acid analog (HAA) pan-histone deacetylase inhibitor (HDACi) currently in early phase clinical development.
A. Kalff, J. Shortt, J. Farr, R. McLennan, A. Lui, J. Scott, A. Spencer   +6 more
doaj   +1 more source

Histone deacetylase adaptation in single ventricle heart disease and a young animal model of right ventricular hypertrophy. [PDF]

, 2017
BackgroundHistone deacetylase (HDAC) inhibitors are promising therapeutics for various forms of cardiac diseases. The purpose of this study was to assess cardiac HDAC catalytic activity and expression in children with single ventricle (SV) heart disease ...
A Cevik, A Correa-Villasenor, A deAlmeida, A Granger, A Kulkarni, AP Vlahos, C Scholz, Carlin S Long, CL Antos, D Sedmera, DD Lemon, DJ Cao, Douglas D Lemon, J Lu, JP Cardinale, JW Newburger, JW Rossano, JW Rossano, Karin Nunley, Katharina M Lutter, KB Schuetze, Kimberly M Demos-Davies, KM Demos-Davies, M Tanno, MA Cavasin, MA Cavasin, Maria A Cavasin, MP Gupta, OA O'Connor, PA Marks, PC Frommelt, Q Yang, R Kirk, RG Ohye, S Chen, Sam Payne, SD Miyamoto, SD Miyamoto, SD Miyamoto, Shelley D Miyamoto, SJ Nakano, SK Mani, SM Williams, TA McKinsey, TG Gillette, Timothy A McKinsey, VM Klimek, Weston W Blakeslee, WJ Kowalski, WW Blakeslee   +49 more
core   +1 more source

Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights

Pharmacology and Therapeutics, 2014
Initially regarded as “epigenetic modifiers” acting predominantly through chromatin remodeling via histone acetylation, HDACIs, alternatively referred to as lysine deacetylase or simply deacetylase inhibitors, have since been recognized to exert multiple
P. Bose, Yun Dai, S. Grant
semanticscholar   +1 more source